New cell therapy aims to boost hearing restoration in cochlear implant patients

NCT ID NCT07032038

Not yet recruiting Disease control Sponsor: Rinri Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This early-stage trial tests a new cell therapy called Rincell-1 for adults with certain types of hearing loss who are getting a cochlear implant. The study will compare the safety and early effectiveness of receiving the cell therapy plus the implant versus the implant alone. About 20 participants will be followed for a year to see if the therapy is safe and can improve hearing nerve function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUDITORY NEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

auditory neuropathy Hearing Loss, Sensorineural presbycusis retrocochlear disease sensorineural hearing loss disorder X-linked mixed hearing loss with perilymphatic gusher

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUDITORY NEUROPATHY PRESBYACUSIS SENSORINEURAL HEARING LOSS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Cambridge University Hospital

Cambridge, United Kingdom
Guy's and St Thomas' Trust

London, United Kingdom
University Hospitals Birmingham

Birmingham, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.